undamentalytics Newsletter
Sign in

Stoke Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Stoke Therapeutics, Inc. had total assets of $418m, total liabilities of $66.0m and shareholders' equity of $352m. It held $84.2m in cash against $0 of debt: net cash of $84.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents11419112884110
Receivables——267
Total current assets244215233306323
Total assets256228272418394
Accounts payable12255
Deferred revenue (current)151519129
Total current liabilities3131405842
Total debt00000
Total liabilities7169436648
Shareholders' equity185160229352346
Net debt (negative = net cash)−114−191−128−84−110
Shares outstanding39m46m54m59m62m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: GLUE vs STOKSTOK vs TNXPARCT vs STOKABEO vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Stoke Therapeutics, Inc.